Physician profile
Tammy Pham
NPI 1982856068
$2,441.81
in general payments reported to CMS, 2019-2025
15 companies · $287 in 2025
The $287 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $254 · 2020: $45.88 · 2021: $51.92 · 2022: $340 · 2023: $803 · 2024: $660 · 2025: $287.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,654 · Entertainment: $96.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,653.78 |
| Entertainment | $96.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $432.16 | 2019-2025 | Clareon, Total30, Precision 1 |
| Johnson & Johnson Vision Care, INC. | $401.56 | 2022-2025 | Acuvue |
| Glaukos Corporation | $272.34 | 2022-2024 | Ce-Marked Kxla System |
| Optovue, INC. | $202.80 | 2019 | |
| Abbvie INC. | $161.92 | 2022-2024 | |
| Dompe US, INC. | $142.47 | 2024 | Oxervate |
| Ocular Therapeutix, INC. | $125.00 | 2024 | Dextenza |
| Oyster Point Pharma, INC. | $121.16 | 2023 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $116.15 | 2025 | |
| Bausch & Lomb Americas INC. | $114.57 | 2022 | |
| Apellis Pharmaceuticals, INC. | $112.07 | 2025 | |
| Coopervision INC. | $100.64 | 2019-2024 | Myday Contact Lens |
| Optos, INC. | $96.35 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $22.62 | 2021 | |
| Biotissue Holdings INC. | $20.00 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.